JPRN-UMIN000011503招募中2 期
Intermediate-cyclophosphamide and bortezomib for peripheral blood stem cell mobilization in multiple myeloma - IDCY-BOR PBSCH Study
Department of Hematology, Ishikawa Prefectural Central Hospital0 个研究点目标入组 20 人开始时间: 2013年8月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Uncontrollable organ dysfunction(liver dysfuction, renal insufficiency, cardiac dysfunction, respiratory dysfunction, diabetes mellitus, infection) 2.Pregnant female 3.HBsAg positive, HCVAb positive, HIVAb positive 4.Coexistence of malignancy 5.Serious mental disorders 6.Those who are considered as inappropriate to register by attending physicians
研究者
相似试验
已完成
2 期
Bortezomib, cyclophosphamide plusd dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myelomaJPRN-UMIN000009765Kanagawa Cancer Center30
已完成
不适用
Bortezomib, Low Dose Cyclophosphamide and G-CSF in Promoting Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell TransplantMultiple MyelomaJPRN-UMIN000021864Ochanomizu Hematology Study Group8
进行中（未招募）
1 期
A study for adults with Waldenstrom's macroglobulinaemia to investigate whether a new combination of 3 drugs (Bortezomib, Cyclophosphamide and Rituxumab) is safe and gives better response to treatment.Waldenstrom's macroglobulinaemia (WM)MedDRA version: 14.1Level: LLTClassification code 10054695Term: Waldenstrom's macroglobulinemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005156-34-GBniversity College London56
尚未招募
3 期
A comparison of Bortezomib, Pomalidomide with low-dose Dexamethasone and Bortezomib, Lenalidomide with low-dose dexamethasone for newly-diagnosed multiple myeloma patients- A randomized phase III study.CTRI/2019/07/020397Dr Lalit Kumar
进行中（未招募）
1 期
Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease.Multiple Myeloma patients presenting with extramedullary diseaseMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2019-000991-41-ITSTICHTING EUROPEAN MYELOMA NETWORK40